Prelude Therapeutics Incorporated (PRLD) Fair Value 2026

PRLD · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-28, Prelude Therapeutics Incorporated (PRLD) trades at $5.47. QOC: 5.8/10. Value Trap Risk: 35/100 (LOW). 1/13 models active.

Key Facts

Ticker
PRLD
Price
$5.47
Quality Score
5.8/10
Value Trap Risk
35/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give PRLD?

1 Intrinsic Value Models vs. Current Price ($5.47)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.44 -91.9%

All Models Active

All 1 models are displayed above.

What Is Prelude Therapeutics Incorporated (PRLD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Prelude Therapeutics Incorporated's intrinsic value is estimated at $0.44. Trading at its current price of $5.47, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -91.9%.

What Do the Models Say About PRLD?

1 of 13 models are currently active for PRLD. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does PRLD Rank in Biotechnology?

Among 625 Biotechnology stocks, PRLD ranks #170 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Prelude Therapeutics Incorporated, metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is PRLD a Value Trap?

CirclFi's Value Trap algorithm assigns PRLD a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Prelude Therapeutics Incorporated. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Prelude Therapeutics Incorporated scores 5.8 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PRLD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PRLD's 1 active models, average confidence is 56%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Prelude Therapeutics Incorporated Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

MRVIMaravai LifeSciences Holdings, Inc.QOC 5.8NAMSNewAmsterdam Pharma Company N.V.QOC 5.8AURAAura Biosciences, Inc.QOC 5.8DNAGinkgo Bioworks Holdings, Inc.QOC 5.8RGNXREGENXBIO Inc.QOC 5.8ABSIAbsci CorporationQOC 5.8GNTAGenenta Science S.p.A.QOC 5.0ONCOOnconetix, Inc.QOC 4.3PBYIPuma Biotechnology, Inc.QOC 8.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: MRVI · NAMS · AURA · DNA · RGNX · ABSI · GNTA · ONCO · PBYI · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PRLD?

6 companies across all industries closest to PRLD’s Quality of Company score of 5.8/10.

ADMTADM Tronics Unlimited, Inc.QOC 5.8AIVApartment Investment and Management CompanyQOC 5.8BNGOBionano Genomics, Inc.QOC 5.8ZHJDIntelligent Hotel Group LtdQOC 5.8BCICBCP Investment Corp.QOC 5.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ADMT · AIV · BNGO · ZHJD · BCIC · NVDA

Where Does PRLD Sit in CirclFi's Biotechnology Rankings?

PRLD is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Prelude Therapeutics Incorporated’s Valuation?

What is Prelude Therapeutics Incorporated's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Prelude Therapeutics Incorporated (PRLD). The Quality of Company score is 5.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PRLD overvalued or undervalued right now?

At $5.47, 0 of 1 active models suggest PRLD may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Prelude Therapeutics Incorporated's business model in Biotechnology.

What does a Quality of Company score of 5.8 mean for PRLD?

Prelude Therapeutics Incorporated's QOC of 5.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PRLD?

CirclFi analyzes PRLD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is PRLD a value trap in 2026?

Prelude Therapeutics Incorporated's Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Prelude Therapeutics Incorporated (PRLD) a Quality of Company score of 5.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/PRLD/ · Methodology
Primary sources for this PRLD valuation
  • Financial statements: Prelude Therapeutics Incorporated 10-K and 10-Q filings on SEC EDGAR (CIK 0001678660) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PRLD as of ; valuations recomputed .